Fig. 2.

Role of BMP6 in hepatic gluconeogenesis. Following BMP6 (100 ng/mL) treatment in H4IIE cells (n = 4) at 12 h, we measured a gene expression by qRT-PCR of fibroblast growth factor 3 (FGF3), fibroblast growth factor receptor 4 (FGFR4), glucose-6-phosphatase (G6Pase), betaKlotho (KLB), phosphoenolpyruvate carboxykinase (PepCK) and pyruvate kinase L/R (PKLR) and hypoxanthine phosphoribosyltransferase 1 (HPRT1). Results are represented as fold change of vehicle expression level, following normalization to HPRT1. b PepCK promoter recruitment was assessed 3 and 7 h following BMP6 (100 ng/mL) treatment by chromatin immunoprecipitation using antibodies against Smad1,2,3,5 and 8 or histone H3 (n = 2). Glucose output (n = 4) was measured following treatment with c increasing BMP6 concentrations at 24 h, and BMP6 (300 ng/mL) and cAMP (0.5 mM) at d 12 and e 24 h. Results are reported as the mean ± STDEV. *p < 0.05, **p < 0.01 vs. control